Literature DB >> 18855584

Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis.

B Jeynes1, J Provias.   

Abstract

There is significant evidence to suggest that a damaged or dysfunctional blood-brain barrier (BBB) may contribute to the pathogenesis of Alzheimer's disease (AD) lesions. Lipoprotein receptor-related protein (LRP-1) and receptor for advanced glycation end products (RAGE) are known to be important (BBB) capillary transport proteins. Altered expression of either of these capillary endothelial LRP-1 and RAGE receptor proteins could indicate a dysfunction of the BBB and its transport regulation of beta-amyloid (Abeta). Cortical samples from the superior temporal (ST) and calcarine occipital (COC) cortices of ten confirmed AD brains and ten comparison group (CG) brains were examined. The densities of neurofibrillary tangles (NFTs), senile plaques (SPs) and LRP-1 and RAGE positive capillaries were recorded and statistically analyzed. There was a statistically significant difference between AD and CG cases and the densities of LRP-1 and RAGE positive capillaries, the AD cases demonstrating the greater numbers. Further, in AD brains there were significant negative correlations between the Abeta burden of SPs and both LRP-1 and RAGE-positive capillaries [p < .001]. Additionally, there was a strong positive correlation between LRP-1 and RAGE capillaries in AD brains [p < .001]. These results suggest that alterations in the LRP-1 and RAGE mediated transport of Abeta take place in AD brains in lesion prone regions and may therefore contribute to SP lesion pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855584     DOI: 10.2174/156720508785908937

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  38 in total

1.  Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain.

Authors:  Joshua B Owen; Rukhsana Sultana; Christopher D Aluise; Michelle A Erickson; Tulin O Price; Guojun Bu; William A Banks; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2010-10-07       Impact factor: 7.376

Review 2.  Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.

Authors:  Tae-In Kam; Youngdae Gwon; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2014-08-24       Impact factor: 9.261

Review 3.  Environmental and Dietary Exposure to Copper and Its Cellular Mechanisms Linking to Alzheimer's Disease.

Authors:  Heng-Wei Hsu; Stephen C Bondy; Masashi Kitazawa
Journal:  Toxicol Sci       Date:  2018-06-01       Impact factor: 4.849

Review 4.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

Review 5.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

Review 6.  Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease.

Authors:  Douglas Walker; Lih Fen Lue; Gaurav Paul; Amar Patel; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2015-01-14       Impact factor: 6.206

Review 7.  The 1st and the 2nd Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update.

Authors:  Claudia Stefanutti
Journal:  Blood Transfus       Date:  2016-07-07       Impact factor: 3.443

8.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

9.  Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia.

Authors:  Tiffany F Hughes; Mary Ganguli
Journal:  Curr Psychiatry Rev       Date:  2009-05-01

10.  ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.

Authors:  Huaqi Xiong; Debbie Callaghan; Aimee Jones; Jianying Bai; Ingrid Rasquinha; Catherine Smith; Ke Pei; Douglas Walker; Lih-Fen Lue; Danica Stanimirovic; Wandong Zhang
Journal:  J Neurosci       Date:  2009-04-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.